Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (BLUE SKY)
OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".
Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.
All patients were documented either in the AMD or DME-module (Full Analysis Set).
For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Aschersleben, Germany, 06449
- Novartis Investigative Site
-
Bayreuth, Germany, 95445
- Novartis Investigative Site
-
Berlin, Germany, 10713
- Novartis Investigative Site
-
Berlin, Germany, 14163
- Novartis Investigative Site
-
Bonn, Germany, 53105
- Novartis Investigative Site
-
Breisach, Germany, 79206
- Novartis Investigative Site
-
Chemnitz, Germany, 09113
- Novartis Investigative Site
-
Cologne, Germany, 50968
- Novartis Investigative Site
-
Dresden, Germany, 01067
- Novartis Investigative Site
-
Dresden, Germany, 01324
- Novartis Investigative Site
-
Esslingen am Neckar, Germany, 73728
- Novartis Investigative Site
-
Glauchau, Germany, 08371
- Novartis Investigative Site
-
Homburg, Germany, 66421
- Novartis Investigative Site
-
Hösbach, Germany, 63768
- Novartis Investigative Site
-
Kiel, Germany, 24103
- Novartis Investigative Site
-
Leipzig, Germany, 04106
- Novartis Investigative Site
-
Magdeburg, Germany, 39104
- Novartis Investigative Site
-
Marienberg, Germany, 09496
- Novartis Investigative Site
-
Münster, Germany, 48145
- Novartis Investigative Site
-
Neubrandenburg, Germany, 17036
- Novartis Investigative Site
-
Schönebeck, Germany, 39218
- Novartis Investigative Site
-
Stralsund, Germany, 18435
- Novartis Investigative Site
-
Sulzbach, Germany, 66280
- Novartis Investigative Site
-
Torgau, Germany, 04860
- Novartis Investigative Site
-
Waren, Germany, 17192
- Novartis Investigative Site
-
Würzburg, Germany, 97080
- Novartis Investigative Site
-
-
Bavaria
-
Munich, Bavaria, Germany, 81377
- Novartis Investigative Site
-
Neuburg A.d. Donau, Bavaria, Germany, 86633
- Novartis Investigative Site
-
Würzburg, Bavaria, Germany, 97080
- Novartis Investigative Site
-
Würzburg, Bavaria, Germany, 97070
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Germany, 60590
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Germany, 37075
- Novartis Investigative Site
-
Osnabrück, Lower Saxony, Germany, 49076
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Germany, 18057
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Trier, Rhineland-Palatinate, Germany, 54296
- Novartis Investigative Site
-
-
Saarland
-
Saarbrücken, Saarland, Germany, 66111
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Germany, 04103
- Novartis Investigative Site
-
Schneeberg, Saxony, Germany, 08289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Germany, 06118
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Germany, 07740
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.
Description
Inclusion Criteria:
The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:
- Diagnosis of nAMD or visual impairment due to DME
- Male and Female nAMD and DME patients with ≥18 years of age at index
- Decision to treat with brolucizumab at baseline visit
- Signed written informed consent
- Patients for whom a therapy with brolucizumab was medically indicated
- Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening
Exclusion Criteria:
- Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
- Patients treated for RVO or CNV other than nAMD
- Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
- Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
- Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
- Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
- Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
- Patients participating in parallel in an interventional clinical trial
- Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
- Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
- Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
- Pregnancy and breast-feeding
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
treatment naïve patients
Patients being the first time treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
|
pre-treated patients
Patients already being treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
Time Frame: Month 12
|
This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). |
Month 12
|
|
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
Time Frame: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Morphological CNV-Changes under clinic specific routine treatment schemes
Time Frame: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Percent of patients maintained on q12w dosing after loading through Week 52
Time Frame: After loading, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study. |
After loading, month 12
|
|
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
Time Frame: Baseline, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. |
Baseline, month 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
Time Frame: Baseline
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Time Frame: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
|
Evaluate VA change from baseline during treatment with brolucizumab
Time Frame: Baseline, month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Baseline, month 24
|
|
Estimate number of anti-VEGF injections, visits and injection intervals
Time Frame: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate percentage of switchers during first 6 months and characterize switchers
Time Frame: Baseline, month 6
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 6
|
|
Estimate discontinuation rate and time to discontinuation
Time Frame: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess retreatment criteria
Time Frame: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the number of OCT
Time Frame: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess the safety of brolucizumab
Time Frame: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate anatomical effectiveness
Time Frame: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate treatment intervals
Time Frame: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Describe implementation of treatment schemes into clinical practice
Time Frame: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
Time Frame: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
Time Frame: Month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 12
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Time Frame: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Characterize VA change from baseline during treatment with brolucizumab
Time Frame: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate discontinuation rate during first year of brolucizumab treatment
Time Frame: Baseline, month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 12
|
|
Estimate time to discontinuation (persistence)
Time Frame: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the treatment burden
Time Frame: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate the number of OCT and the number of visits with/without OCT
Time Frame: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Month 1-12 and 13-24
|
|
Assess safety of brolucizumab
Time Frame: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRTH258ADE02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.